Document And Entity Information
Document And Entity Information | 3 Months Ended |
Mar. 31, 2020 | |
Document Information [Line Items] | |
Entity Registrant Name | BeyondSpring Inc. |
Entity Central Index Key | 0001677940 |
Current Fiscal Year End Date | --12-31 |
Document Type | 6-K |
Document Period End Date | Mar. 31, 2020 |
Document Fiscal Year Focus | 2020 |
Document Fiscal Period Focus | Q1 |
Amendment Flag | false |
Audited Consolidated Balance Sh
Audited Consolidated Balance Sheet as of December 31, 2019 and Unaudited Interim Condensed Consolidated Balance Sheet as of March 31, 2020 - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 24,917 | $ 35,933 |
Advances to suppliers | 4,384 | 4,519 |
Prepaid expenses and other current assets | 452 | 410 |
Total current assets | 29,753 | 40,862 |
Noncurrent assets: | ||
Property and equipment, net | 203 | 209 |
Operating lease right-of-use assets | 2,607 | 2,538 |
Other noncurrent assets | 941 | 946 |
Total noncurrent assets | 3,751 | 3,693 |
Total assets | 33,504 | 44,555 |
Current liabilities: | ||
Accounts payable | 5,140 | 2,537 |
Accrued expenses | 4,697 | 5,861 |
Due to related parties | 42 | 29 |
Current portion of operating lease liabilities | 643 | 537 |
Other current liabilities | 1,685 | 1,089 |
Total current liabilities | 12,207 | 10,053 |
Noncurrent liabilities: | ||
Long-term loans | 1,413 | 1,436 |
Operating lease liabilities | 1,892 | 1,935 |
Total noncurrent liabilities | 3,305 | 3,371 |
Total liabilities | 15,512 | 13,424 |
Equity: | ||
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 27,885,613 shares and 27,888,906 shares issued and outstanding as of December 31, 2019 and March 31, 2020, respectively) | 3 | 3 |
Additional paid-in capital | 250,417 | 246,979 |
Accumulated deficit | (232,929) | (216,845) |
Accumulated other comprehensive income | 197 | 140 |
Total BeyondSpring Inc.’s shareholder’s equity | 17,688 | 30,277 |
Noncontrolling interests | 304 | 854 |
Total equity | 17,992 | 31,131 |
Total liabilities and equity | $ 33,504 | $ 44,555 |
Audited Consolidated Balance _2
Audited Consolidated Balance Sheet as of December 31, 2019 and Unaudited Interim Condensed Consolidated Balance Sheet as of March 31, 2020 (Parentheticals) - $ / shares | Mar. 31, 2020 | Dec. 31, 2019 |
Ordinary shares, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Ordinary shares, authorized (in shares) | 500,000,000 | 500,000,000 |
Ordinary shares, issued (in shares) | 27,888,906 | 27,885,613 |
Ordinary shares, outstanding (in shares) | 27,888,906 | 27,885,613 |
Unaudited Interim Condensed Con
Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2019 and 2020 - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenue | ||
Operating expenses: | ||
Research and development | (13,704) | (6,330) |
Selling, general and administrative | (2,928) | (1,639) |
Loss from operations | (16,632) | (7,969) |
Foreign exchange gain (loss), net | (74) | 173 |
Interest income | 64 | 6 |
Interest expense | (21) | (37) |
Other income | 1 | |
Loss before income tax | (16,662) | (7,827) |
Income tax benefit | 0 | 0 |
Net loss | (16,662) | (7,827) |
Less: Net loss attributable to noncontrolling interests | (578) | (534) |
Net loss attributable to BeyondSpring Inc. | $ (16,084) | $ (7,293) |
Net loss per share | ||
Basic and diluted (in dollars per share) | $ (0.58) | $ (0.32) |
Weighted-average shares outstanding | ||
Basic and diluted (in shares) | 27,732,449 | 23,029,362 |
Other comprehensive loss | ||
Foreign currency translation adjustment (loss) gain | $ 53 | $ (194) |
Comprehensive loss | (16,609) | (8,021) |
Less: Comprehensive loss attributable to noncontrolling interests | (582) | (575) |
Comprehensive loss attributable to BeyondSpring Inc. | $ (16,027) | $ (7,446) |
Unaudited Interim Condensed C_2
Unaudited Interim Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2019 and 2020 - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Operating activities: | ||
Net loss | $ (16,662) | $ (7,827) |
Adjustments to reconcile net loss to net cash from operating activities: | ||
Share-based compensation | 3,470 | 371 |
Depreciation expenses | 15 | 23 |
Changes in operating assets and liabilities: | ||
Advances to suppliers | 135 | 143 |
Due from related parties | 100 | |
Prepaid expenses and other current assets | (42) | 123 |
Operating lease right-of-use assets | (69) | 134 |
Other noncurrent assets | 5 | (60) |
Accounts payable | 2,603 | (620) |
Accrued expenses | (1,164) | 2,377 |
Operating lease liabilities | 63 | (56) |
Other current liabilities | 596 | 232 |
Net cash used in operating activities | (11,050) | (5,060) |
Investing activities: | ||
Acquisitions of property and equipment | (9) | (4) |
Net cash used in investing activities | (9) | (4) |
Financing activities: | ||
Proceeds from loans | 2,986 | |
Loans from related parties | 14 | 350 |
Net cash provided by financing activities | 14 | 3,336 |
Effect of foreign exchange rate changes, net | 29 | (200) |
Net decrease in cash and cash equivalents | (11,016) | (1,928) |
Cash at beginning of period | 35,933 | 3,889 |
Cash at end of period | $ 24,917 | $ 1,961 |
Note 1 - Nature of the Business
Note 1 - Nature of the Business and Basis of Preparation | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Nature of the business and basis of preparation BeyondSpring Inc. (the “Company”) was incorporated in the Cayman Islands on November 21, 2014. As of March 31, 2020, Name of company Place of incorporation Date of Percentage of Principal activities BeyondSpring Delaware, Pharmaceuticals Inc. United States of America (“U.S.”) June 18, 2013 100% Clinical trial activities BeyondSpring Ltd. The British Virgin Islands (“BVI”) December 3, 2014 100% Holding company BeyondSpring (HK) Limited Hong Kong January 13, 2015 100% Holding company Wanchun Biotechnology Limited BVI April 1, 2015 100% Holding company Wanchun Biotechnology The People’s Republic of China (Shenzhen) Ltd. (“PRC”) April 23, 2015 100% Holding company Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) PRC May 6, 2015 57.97% Clinical trial activities BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) Australia March 3, 2016 100% Clinical trial activities Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) PRC May 21, 2018 57.97% Clinical trial activities SEED Therapeutics Inc. (“SEED”) BVI June 25, 2019 100% Holding company SEED Technology Limited (“SEED Technology”) BVI December 9, 2019 57.97% Holding company The accompanying unaudited interim condensed consolidated balance sheet as of March 31, 2020, three March 31, 2019 2020, three March 31, 2019 2020, December 31, 2019. not In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Group for each of the periods presented. The results of operations for the three March 31, 2020 not 2020. December 31, 2019 not December 31, 2019. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of significant accounting policies Basis of consolidation The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Going concern According to Accounting Standards Codification (“ASC”) 205 40, Presentation of Financial Statements - Going Concern 205 40” one not not 1 one 2 one The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no $16,662 three March 31, 2020 $232,929 March 31, 2020. $11,050 three March 31, 2020. March 31, 2020, $17,546 $24,917 The Company is implementing a cost reduction plan, which includes the deferral of certain research, development and clinical projects and reduction of administrative expenses until it obtains additional financings. With the implementation of cost reduction plan, the Company anticipates that its current financial resources will enable it to meet its operational expenses and capital expenditures into the second 2021. Therefore, the management believes that the substantial doubt about the Company’s ability to continue as a going concern within one Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not Fair value measurements The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three • Level 1— • Level 2— • Level 3— no ASC 820, Fair Value Measurements and Disclosures 820” three 1 2 3 Financial instruments of the Company primarily include cash and cash equivalents, due from related parties, due to related parties, accounts payable and long-term loans. Except for the long-term loans, the carrying values of these financial instruments approximated their fair value due to their short term nature as of December 31, 2019 March 31, 2020. As of December 31, 2019 March 31, 2020, $1,436 $1,413, $1,373 $1,214, 2 Recent accounting pronouncements New accounting standard have not In December 2019, 2019 12, Income Taxes (Topic 740 740, December 15, 2020, |
Note 3 - Property and Equipment
Note 3 - Property and Equipment, Net | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 3. Property and equipment, net Property and equipment consist of the following: December 31, March 31, 2019 2020 $ $ (Unaudited) Office equipment 150 161 Laboratory equipment 114 113 Motor vehicles 23 22 Leasehold improvements 103 103 390 399 Less: accumulated depreciation (181 ) (196 ) Property and equipment, net 209 203 Depreciation expenses for the three March 31, 2019 2020 $23 $15, |
Note 4 - Long-term Loans
Note 4 - Long-term Loans | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 4. Long-term loans On March 28, 2019, three $1,493 RMB10,000 120.0% three March 28, 2022. |
Note 5 - Related Party Transact
Note 5 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 5. Related party transactions Loan from related parties In October December 2019, 60 $29 RMB200 February 2020, 60 $14 RMB100 June 2020. |
Note 6 - Income Taxes
Note 6 - Income Taxes | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 6. Income taxes There is no three March 31, 2019 2020. The Company recorded a full valuation allowance against deferred tax assets for all periods presented. There were no three March 31, 2020. not 12 |
Note 7 - Equity
Note 7 - Equity | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 7. Equity The movement of equity is as follows : BeyondSpring Inc.’s shareholders Accumulated Additional other Non Total Ordinary share paid-in Accumulated comprehensive Subtotal controlling equity Shares Amount capital deficit (loss) gain interests (deficit) $ $ $ $ $ $ $ Balances at January 1, 2020 (audited) 27,885,613 3 246,979 (216,845 ) 140 30,277 854 31,131 Share-based compensation 3,293 - 3,438 - - 3,438 32 3,470 Foreign currency translation adjustment (loss) gain - - - - 57 57 (4 ) 53 Net loss - - - (16,084 ) - (16,084 ) (578 ) (16,662 ) Balances at March 31, 2020 (unaudited) 27,888,906 3 250,417 (232,929 ) 197 17,688 304 17,992 Balances at January 1, 2019 (audited) 23,184,612 2 170,950 (178,760 ) 42 (7,766 ) (1,616 ) (9,382 ) Share-based compensation - - 371 - - 371 - 371 Foreign currency translation adjustment loss - - - - (153 ) (153 ) (41 ) (194 ) Net loss - - - (7,293 ) - (7,293 ) (534 ) (7,827 ) Balances at March 31, 2019 (unaudited) 23,184,612 2 171,321 (186,053 ) (111 ) (14,841 ) (2,191 ) (17,032 ) |
Note 8 - Restricted Net Assets
Note 8 - Restricted Net Assets | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Restricted Assets Disclosure [Text Block] | 8. Restricted net assets As a result of PRC laws and regulations, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company. As of December 31, 2019 March 31, 2020, $2,032 $329, |
Note 9 - Employee Defined Contr
Note 9 - Employee Defined Contribution Plan | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | 9. Employee defined contribution plan Full time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company’s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees’ salaries. The Company has no $15 $26 three March 31, 2019 2020, |
Note 10 - Net Loss Per Share
Note 10 - Net Loss Per Share | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 10. Net loss per share Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows: Three months ended March 31, 2019 2020 (Unaudited) (Unaudited) Numerator: Net loss attributable to BeyondSpring Inc.—basic and diluted $ (7,293 ) $ (16,084 ) Denominator: Weighted average number of ordinary shares outstanding—basic and diluted 23,029,362 27,732,449 Net loss per share —basic and diluted $ (0.32 ) $ (0.58 ) The effects of restricted shares and share options were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the three March 31, 2019 2020. |
Note 11 - Supplemental Balance
Note 11 - Supplemental Balance Sheet Information | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 11. Supplemental balance sheet information Other current liabilities consist of the following: As of December 31, As of March 31, 2019 2020 $ $ (Unaudited) Compensation related 226 207 Professional services - 543 Other taxes related 798 810 Other 65 125 Total 1,089 1,685 |
Note 12 - Share-based Compensat
Note 12 - Share-based Compensation | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 12. Share-based compensation During the three March 31, 2020, 381,301 3,293 The following table summarizes total share-based compensation expense recognized for the three March 31, 2019 2020: Three months ended March 31, 2019 2020 $ $ (Unaudited) (Unaudited) Research and development 156 3,183 Selling, general and administrative 215 287 Total 371 3,470 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of consolidation The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. |
Going Concern, Policy [Policy Text Block} | Going concern According to Accounting Standards Codification (“ASC”) 205 40, Presentation of Financial Statements - Going Concern 205 40” one not not 1 one 2 one The Company has incurred operating losses and negative cash flows from operations since inception. To date, the Company has no $16,662 three March 31, 2020 $232,929 March 31, 2020. $11,050 three March 31, 2020. March 31, 2020, $17,546 $24,917 The Company is implementing a cost reduction plan, which includes the deferral of certain research, development and clinical projects and reduction of administrative expenses until it obtains additional financings. With the implementation of cost reduction plan, the Company anticipates that its current financial resources will enable it to meet its operational expenses and capital expenditures into the second 2021. Therefore, the management believes that the substantial doubt about the Company’s ability to continue as a going concern within one |
Use of Estimates, Policy [Policy Text Block] | Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair value measurements The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three • Level 1— • Level 2— • Level 3— no ASC 820, Fair Value Measurements and Disclosures 820” three 1 2 3 Financial instruments of the Company primarily include cash and cash equivalents, due from related parties, due to related parties, accounts payable and long-term loans. Except for the long-term loans, the carrying values of these financial instruments approximated their fair value due to their short term nature as of December 31, 2019 March 31, 2020. As of December 31, 2019 March 31, 2020, $1,436 $1,413, $1,373 $1,214, 2 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent accounting pronouncements New accounting standard have not In December 2019, 2019 12, Income Taxes (Topic 740 740, December 15, 2020, |
Note 1 - Nature of the Busine_2
Note 1 - Nature of the Business and Basis of Preparation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Subsidiaries [Table Text Block] | Name of company Place of incorporation Date of Percentage of Principal activities BeyondSpring Delaware, Pharmaceuticals Inc. United States of America (“U.S.”) June 18, 2013 100% Clinical trial activities BeyondSpring Ltd. The British Virgin Islands (“BVI”) December 3, 2014 100% Holding company BeyondSpring (HK) Limited Hong Kong January 13, 2015 100% Holding company Wanchun Biotechnology Limited BVI April 1, 2015 100% Holding company Wanchun Biotechnology The People’s Republic of China (Shenzhen) Ltd. (“PRC”) April 23, 2015 100% Holding company Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) PRC May 6, 2015 57.97% Clinical trial activities BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) Australia March 3, 2016 100% Clinical trial activities Beijing Wanchun Pharmaceutical Technology Ltd. (“Beijing Wanchun”) PRC May 21, 2018 57.97% Clinical trial activities SEED Therapeutics Inc. (“SEED”) BVI June 25, 2019 100% Holding company SEED Technology Limited (“SEED Technology”) BVI December 9, 2019 57.97% Holding company |
Note 3 - Property and Equipme_2
Note 3 - Property and Equipment, Net (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, March 31, 2019 2020 $ $ (Unaudited) Office equipment 150 161 Laboratory equipment 114 113 Motor vehicles 23 22 Leasehold improvements 103 103 390 399 Less: accumulated depreciation (181 ) (196 ) Property and equipment, net 209 203 |
Note 7 - Equity (Tables)
Note 7 - Equity (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Stockholders Equity [Table Text Block] | BeyondSpring Inc.’s shareholders Accumulated Additional other Non Total Ordinary share paid-in Accumulated comprehensive Subtotal controlling equity Shares Amount capital deficit (loss) gain interests (deficit) $ $ $ $ $ $ $ Balances at January 1, 2020 (audited) 27,885,613 3 246,979 (216,845 ) 140 30,277 854 31,131 Share-based compensation 3,293 - 3,438 - - 3,438 32 3,470 Foreign currency translation adjustment (loss) gain - - - - 57 57 (4 ) 53 Net loss - - - (16,084 ) - (16,084 ) (578 ) (16,662 ) Balances at March 31, 2020 (unaudited) 27,888,906 3 250,417 (232,929 ) 197 17,688 304 17,992 Balances at January 1, 2019 (audited) 23,184,612 2 170,950 (178,760 ) 42 (7,766 ) (1,616 ) (9,382 ) Share-based compensation - - 371 - - 371 - 371 Foreign currency translation adjustment loss - - - - (153 ) (153 ) (41 ) (194 ) Net loss - - - (7,293 ) - (7,293 ) (534 ) (7,827 ) Balances at March 31, 2019 (unaudited) 23,184,612 2 171,321 (186,053 ) (111 ) (14,841 ) (2,191 ) (17,032 ) |
Note 10 - Net Loss Per Share (T
Note 10 - Net Loss Per Share (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three months ended March 31, 2019 2020 (Unaudited) (Unaudited) Numerator: Net loss attributable to BeyondSpring Inc.—basic and diluted $ (7,293 ) $ (16,084 ) Denominator: Weighted average number of ordinary shares outstanding—basic and diluted 23,029,362 27,732,449 Net loss per share —basic and diluted $ (0.32 ) $ (0.58 ) |
Note 11 - Supplemental Balanc_2
Note 11 - Supplemental Balance Sheet Information (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Other Current Liabilities [Table Text Block] | As of December 31, As of March 31, 2019 2020 $ $ (Unaudited) Compensation related 226 207 Professional services - 543 Other taxes related 798 810 Other 65 125 Total 1,089 1,685 |
Note 12 - Share-based Compens_2
Note 12 - Share-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three months ended March 31, 2019 2020 $ $ (Unaudited) (Unaudited) Research and development 156 3,183 Selling, general and administrative 215 287 Total 371 3,470 |
Note 1 - Nature of the Busine_3
Note 1 - Nature of the Business and Basis of Preparation - Schedule of Subsidiaries (Details) | Mar. 31, 2020 |
BeyondSpring Pharmaceuticals Inc. [Member] | |
Equity method investment, ownership percentage | 100.00% |
BeyondSpring Ltd. [Member] | |
Equity method investment, ownership percentage | 100.00% |
BeyondSpring HK [Member] | |
Equity method investment, ownership percentage | 100.00% |
Wanchun Biotechnology Limited [Member] | |
Equity method investment, ownership percentage | 100.00% |
Wanchun Biotechnology (Shenzhen) Ltd. [Member] | |
Equity method investment, ownership percentage | 100.00% |
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member] | |
Equity method investment, ownership percentage | 57.97% |
BeyondSpring Pharmaceuticals Australia PTY Ltd. (“BeyondSpring Australia”) [Member] | |
Equity method investment, ownership percentage | 100.00% |
Beijing Wanchun Pharmaceutical Technology Ltd. [Member] | |
Equity method investment, ownership percentage | 57.97% |
SEED Therapuetics Inc. [Member] | |
Equity method investment, ownership percentage | 100.00% |
SEED Technology Limited [Member] | |
Equity method investment, ownership percentage | 57.97% |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 0 | |||
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total | (16,662) | (7,827) | ||
Retained Earnings (Accumulated Deficit), Ending Balance | (232,929) | (216,845) | ||
Net Cash Provided by (Used in) Operating Activities, Total | (11,050) | (5,060) | ||
Net Current Assets | 17,546 | |||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 24,917 | $ 1,961 | 35,933 | $ 3,889 |
Long-term Debt, Total | 1,413 | 1,436 | ||
Long-term Debt, Fair Value | $ 1,214 | $ 1,373 |
Note 3 - Property and Equipme_3
Note 3 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Depreciation, Total | $ 15 | $ 23 |
Note 3 - Property and Equipme_4
Note 3 - Property and Equipment, Net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Property, plant, and equipment, gross | $ 399 | $ 390 |
Less: accumulated depreciation | (196) | (181) |
Property and equipment, net | 203 | 209 |
Office Equipment [Member] | ||
Property, plant, and equipment, gross | 161 | 150 |
Laboratory Equipment [Member] | ||
Property, plant, and equipment, gross | 113 | 114 |
Automobiles [Member] | ||
Property, plant, and equipment, gross | 22 | 23 |
Leasehold Improvements [Member] | ||
Property, plant, and equipment, gross | $ 103 | $ 103 |
Note 4 - Long-term Loans (Detai
Note 4 - Long-term Loans (Details Textual) $ in Thousands, ¥ in Millions | Mar. 28, 2019USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Mar. 28, 2019CNY (¥) |
Long-term Debt, Total | $ 1,413 | $ 1,436 | ||
Term Loan [Member] | China Construction Bank [Member] | ||||
Debt Instrument, Term (Year) | 3 years | |||
Long-term Debt, Total | $ 1,493 | ¥ 10 | ||
Term Loan [Member] | China Construction Bank [Member] | Three Yearr Loan Interest Rate Quoted by People's Bank of China [Member] | ||||
Debt Instrument, Annual Interest Rate Based on Variable Rate | 120.00% |
Note 5 - Related Party Transa_2
Note 5 - Related Party Transactions (Details Textual) $ in Thousands, ¥ in Millions | 1 Months Ended | 3 Months Ended | ||
Feb. 28, 2020USD ($) | Feb. 28, 2020CNY (¥) | Dec. 31, 2019USD ($) | Dec. 31, 2019CNY (¥) | |
Dalian Wanchun Biotechnology Co., Ltd. [Member] | ||||
Proceeds from Short-term Debt, Total | $ 14 | ¥ 0.1 | $ 29 | ¥ 0.2 |
Note 6 - Income Taxes (Details
Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Income Tax Expense (Benefit), Total | $ 0 | $ 0 |
Note 7 - Equity - Schedule of S
Note 7 - Equity - Schedule of Stockholders' Equity (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Balances | $ 31,131 | $ (9,382) |
Share-based compensation | 3,470 | |
Foreign currency translation adjustment (loss) gain | 53 | (194) |
Net loss | (16,662) | (7,827) |
Share-based compensation | 371 | |
Balances | $ 17,992 | $ (17,032) |
Common Stock [Member] | ||
Balances (in shares) | 27,885,613 | 23,184,612 |
Balances | $ 3 | $ 2 |
Share-based compensation (in shares) | 3,293 | |
Share-based compensation | ||
Foreign currency translation adjustment (loss) gain | ||
Net loss | ||
Share-based compensation | ||
Balances (in shares) | 27,888,906 | 23,184,612 |
Balances | $ 3 | $ 2 |
Additional Paid-in Capital [Member] | ||
Balances | 246,979 | 170,950 |
Share-based compensation | 3,438 | |
Foreign currency translation adjustment (loss) gain | ||
Net loss | ||
Share-based compensation | 371 | |
Balances | 250,417 | 171,321 |
Retained Earnings [Member] | ||
Balances | (216,845) | (178,760) |
Share-based compensation | ||
Foreign currency translation adjustment (loss) gain | ||
Net loss | (16,084) | (7,293) |
Share-based compensation | ||
Balances | (232,929) | (186,053) |
AOCI Attributable to Parent [Member] | ||
Balances | 140 | 42 |
Share-based compensation | ||
Foreign currency translation adjustment (loss) gain | 57 | (153) |
Net loss | ||
Share-based compensation | ||
Balances | 197 | (111) |
Parent [Member] | ||
Balances | 30,277 | (7,766) |
Share-based compensation | 3,438 | |
Foreign currency translation adjustment (loss) gain | 57 | (153) |
Net loss | (16,084) | (7,293) |
Share-based compensation | 371 | |
Balances | 17,688 | (14,841) |
Noncontrolling Interest [Member] | ||
Balances | 854 | (1,616) |
Share-based compensation | 32 | |
Foreign currency translation adjustment (loss) gain | (4) | (41) |
Net loss | (578) | (534) |
Share-based compensation | ||
Balances | $ 304 | $ (2,191) |
Note 8 - Restricted Net Assets
Note 8 - Restricted Net Assets (Details Textual) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Restricted Net Assets | $ 329 | $ 2,032 |
Note 9 - Employee Defined Con_2
Note 9 - Employee Defined Contribution Plan (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Defined Contribution Plan, Cost | $ 26 | $ 15 |
Note 10 - Net Loss Per Share -
Note 10 - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Net loss attributable to BeyondSpring Inc.—basic and diluted | $ (16,084) | $ (7,293) |
Weighted average number of ordinary shares outstanding—basic and diluted (in shares) | 27,732,449 | 23,029,362 |
Net loss per share —basic and diluted (in dollars per share) | $ (0.58) | $ (0.32) |
Note 11 - Supplemental Balanc_3
Note 11 - Supplemental Balance Sheet Information - Other Current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Compensation related | $ 207 | $ 226 |
Professional services | 543 | |
Other taxes related | 810 | 798 |
Other | 125 | 65 |
Total | $ 1,685 | $ 1,089 |
Note 12 - Share-based Compens_3
Note 12 - Share-based Compensation (Details Textual) | 3 Months Ended |
Mar. 31, 2020shares | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 381,301 |
Restricted Stock [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 3,293 |
Note 12 - Share-based Compens_4
Note 12 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Allocated Share-based Compensation Expense | $ 3,470 | $ 371 |
Research and Development Expense [Member] | ||
Allocated Share-based Compensation Expense | 3,183 | 156 |
General and Administrative Expense [Member] | ||
Allocated Share-based Compensation Expense | $ 287 | $ 215 |